In vitro sensitivity of clonogenic cells in resisting and relapsing patients with acute myelogenous leukaemia.
In vitro sensitivity of clonogenic cells in resisting and relapsing patients with acute myelogenous leukaemia.
复制标题
DOI：
10.1038/bjc.1988.261
复制
发表时间：
1988-11
影响因子：
8.8
通讯作者：
Thevenin D
中科院分区：
文献类型：
--
作者：
Marie JP;Zittoun R;Thevenin D
本文对23例急性髓系白血病患者用蒽环类抗生素和阿糖胞苷（ara-C）治疗后，骨髓集落形成细胞（CFU-L）体外药物敏感性的变化进行了研究。在首次诱导治疗失败前后（间隔：6 ± 4周）检测的12例患者中，柔红霉素的敏感性保持稳定，阿糖胞苷的敏感性变化不大。在治疗前和首次复发时（间隔：13 +/-7个月）检测的11名患者中，体外CFU-L敏感性显示两种测量值之间无相关性，并且对柔红霉素和阿糖胞苷的敏感性呈下降趋势。这些发现表明，诱导失败可能与耐药CFU-L亚克隆的简单选择以外的因素有关。
The evolution of in vitro bone marrow clonogenic leukaemic cells (CFU-L) drug sensitivity was studied in 23 patients with acute myeloid leukaemia treated with anthracycline and cytosine arbinoside (ara-C). In 12 patients tested before and after first induction treatment failure (interval: 6 +/- 4 weeks), the sensitivity remained stable for daunorubicin and showed little variation for ara-C. Among eleven patients tested before treatment and at first relapse (interval: 13 +/- 7 months), in vitro CFU-L sensitivity revealed no correlation between the two measurements, and a trend in decreased sensitivity to daunorubicin and ara-C. These findings suggest that induction failures could be related to factors other than simple selection of a resistant CFU-L subclone.